MAP2K7 and cancer: Efficacy has also been demonstrated in BCR-ABL-driven chronic myeloid leukemia CML (Gu et al., 2018), where SHP2 is a strong inducer of MEK/ERK signaling and through disruption of RTK-mediated feedback signaling in RAS-driven cancers (Wong et al., 2018).